Head-and-Neck Cancer Clinical Trials
EORTC1206-HNCG: A randomised phase II study to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy in patients with recurrent and/or metastatic, androgen receptor expressing, salivary gland cancer.
Open to recruitment
DARS: A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer.
In active follow-up
ART DECO: A phase III multi-centre randomised controlled trial to determine the potential of dose escalated IMRT to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.
COSTAR: COchlear Sparing Therapy And conventional Radiation - a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz.
PARSPORT: PARSPORT is a Phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.